Trial Title:
Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body
NCT ID:
NCT06470243
Condition:
Castration-Resistant Prostate Carcinoma
Stage IVB Prostate Cancer AJCC v8
Conditions: Official terms:
Prostatic Neoplasms
Prednisone
Cortisone
Carboplatin
Study type:
Interventional
Study phase:
Phase 3
Overall status:
Recruiting
Study design:
Allocation:
Randomized
Intervention model:
Parallel Assignment
Primary purpose:
Treatment
Masking:
None (Open Label)
Intervention:
Intervention type:
Procedure
Intervention name:
Biospecimen Collection
Description:
Undergo blood sample collection
Arm group label:
Arm 1 (cabazitaxel, prednisone)
Arm group label:
Arm 2 (cabazitaxel, carboplatin, prednisone)
Other name:
Biological Sample Collection
Other name:
Biospecimen Collected
Other name:
Specimen Collection
Intervention type:
Procedure
Intervention name:
Bone Scan
Description:
Undergo bone scan
Arm group label:
Arm 1 (cabazitaxel, prednisone)
Arm group label:
Arm 2 (cabazitaxel, carboplatin, prednisone)
Other name:
Bone Scintigraphy
Intervention type:
Drug
Intervention name:
Cabazitaxel
Description:
Given IV
Arm group label:
Arm 1 (cabazitaxel, prednisone)
Arm group label:
Arm 2 (cabazitaxel, carboplatin, prednisone)
Other name:
Jevtana
Other name:
RPR-116258A
Other name:
RPR116258A
Other name:
Taxoid XRP6258
Other name:
TXD258
Other name:
XRP-6258
Other name:
XRP6258
Intervention type:
Drug
Intervention name:
Carboplatin
Description:
Given IV
Arm group label:
Arm 2 (cabazitaxel, carboplatin, prednisone)
Other name:
Blastocarb
Other name:
Carboplat
Other name:
Carboplatin Hexal
Other name:
Carboplatino
Other name:
Carboplatinum
Other name:
Carbosin
Other name:
Carbosol
Other name:
Carbotec
Other name:
CBDCA
Other name:
Displata
Other name:
Ercar
Other name:
JM-8
Other name:
JM8
Other name:
Nealorin
Other name:
Novoplatinum
Other name:
Paraplatin
Other name:
Paraplatin AQ
Other name:
Paraplatine
Other name:
Platinwas
Other name:
Ribocarbo
Intervention type:
Procedure
Intervention name:
Chest Radiography
Description:
Undergo chest x-ray
Arm group label:
Arm 1 (cabazitaxel, prednisone)
Arm group label:
Arm 2 (cabazitaxel, carboplatin, prednisone)
Other name:
Chest X-ray
Intervention type:
Procedure
Intervention name:
Computed Tomography
Description:
Undergo CT or PET/CT
Arm group label:
Arm 1 (cabazitaxel, prednisone)
Arm group label:
Arm 2 (cabazitaxel, carboplatin, prednisone)
Other name:
CAT
Other name:
CAT Scan
Other name:
Computed Axial Tomography
Other name:
Computerized Axial Tomography
Other name:
Computerized axial tomography (procedure)
Other name:
Computerized Tomography
Other name:
Computerized Tomography (CT) scan
Other name:
CT
Other name:
CT Scan
Other name:
tomography
Intervention type:
Procedure
Intervention name:
Magnetic Resonance Imaging
Description:
Undergo MRI
Arm group label:
Arm 1 (cabazitaxel, prednisone)
Arm group label:
Arm 2 (cabazitaxel, carboplatin, prednisone)
Other name:
Magnetic Resonance
Other name:
Magnetic Resonance Imaging (MRI)
Other name:
Magnetic resonance imaging (procedure)
Other name:
Magnetic Resonance Imaging Scan
Other name:
Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance
Other name:
MR
Other name:
MR Imaging
Other name:
MRI
Other name:
MRI Scan
Other name:
MRIs
Other name:
NMR Imaging
Other name:
NMRI
Other name:
Nuclear Magnetic Resonance Imaging
Other name:
sMRI
Other name:
Structural MRI
Intervention type:
Procedure
Intervention name:
Positron Emission Tomography
Description:
Undergo PET/CT
Arm group label:
Arm 1 (cabazitaxel, prednisone)
Arm group label:
Arm 2 (cabazitaxel, carboplatin, prednisone)
Other name:
Medical Imaging, Positron Emission Tomography
Other name:
PET
Other name:
PET Scan
Other name:
Positron emission tomography (procedure)
Other name:
Positron Emission Tomography Scan
Other name:
Positron-Emission Tomography
Other name:
proton magnetic resonance spectroscopic imaging
Other name:
PT
Intervention type:
Drug
Intervention name:
Prednisone
Description:
Given PO
Arm group label:
Arm 1 (cabazitaxel, prednisone)
Arm group label:
Arm 2 (cabazitaxel, carboplatin, prednisone)
Other name:
.delta.1-Cortisone
Other name:
1, 2-Dehydrocortisone
Other name:
Adasone
Other name:
Cortancyl
Other name:
Dacortin
Other name:
DeCortin
Other name:
Decortisyl
Other name:
Decorton
Other name:
Delta 1-Cortisone
Other name:
Delta-Dome
Other name:
Deltacortene
Other name:
Deltacortisone
Other name:
Deltadehydrocortisone
Other name:
Deltasone
Other name:
Deltison
Other name:
Deltra
Other name:
Econosone
Other name:
Lisacort
Other name:
Meprosona-F
Other name:
Metacortandracin
Other name:
Meticorten
Other name:
Ofisolona
Other name:
Orasone
Other name:
Panafcort
Other name:
Panasol-S
Other name:
Paracort
Other name:
Perrigo Prednisone
Other name:
PRED
Other name:
Predicor
Other name:
Predicorten
Other name:
Prednicen-M
Other name:
Prednicort
Other name:
Prednidib
Other name:
Prednilonga
Other name:
Predniment
Other name:
Prednisone Intensol
Other name:
Prednisonum
Other name:
Prednitone
Other name:
Promifen
Other name:
Rayos
Other name:
Servisone
Other name:
SK-Prednisone
Summary:
This phase III trial compares the effect of adding carboplatin to the standard of care
chemotherapy drug cabazitaxel versus cabazitaxel alone in treating prostate cancer that
keeps growing even when the amount of testosterone in the body is reduced to very low
levels (castrate-resistant) and that has spread from where it first started (primary
site) to other places in the body (metastatic). Carboplatin is in a class of medications
known as platinum-containing compounds. Carboplatin works by killing, stopping or slowing
the growth of tumor cells. Chemotherapy drugs, such as cabazitaxel, work in different
ways to stop the growth of tumor cells, either by killing the cells, by stopping them
from dividing, or by stopping them from spreading. Prednisone is often given together
with chemotherapy drugs. Prednisone is in a class of medications called corticosteroids.
It is used to reduce inflammation and lower the body's immune response to help lessen the
side effects of chemotherapy drugs and to help the chemotherapy work. Giving carboplatin
with the standard of care chemotherapy drug cabazitaxel may be better at treating
metastatic castrate-resistant prostate cancer.
Detailed description:
PRIMARY OBJECTIVES:
I. To compare radiographic progression free survival (rPFS) between the two treatment
arms in the subset of aggressive variant prostate cancer - molecular-pathologic signature
(AVPC-MS)-positive participants.
II. If the AVPC-MS positive test is statistically significant, test in AVPC-MS negative
participants whether the combination of carboplatin and cabazitaxel improves rPFS.
SECONDARY OBJECTIVES:
I. To compare overall survival (OS) between the two treatment arms, stratified by AVPC-MS
positive versus (vs.) negative.
II. To compare response rates for prostate specific antigen (PSA), total alkaline
phosphatase, and Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 between the
two treatment arms, stratified by AVPC-MS positive vs. negative.
III. To compare rPFS between the two treatment arms for the full trial. IV. To compare
rPFS between the two treatment arms for the AVPC-MS negative group in the absence of a
positive treatment effect in the AVPC-MS positive group.
V. To compare progression free survival (PFS) between the two treatment arms, stratified
by AVPC-MS positive vs. negative.
VI. To compare toxicities between the two arms in participants who receive any treatment
on study.
BANKING OBJECTIVES:
I. To bank specimens for future correlative studies.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM 1: Patients receive cabazitaxel intravenously (IV) over 60 minutes on day 1 of each
cycle and prednisone orally (PO) twice daily (BID) on days 1-21 of each cycle. Cycles
repeat every 21 days for up to 10 cycles in the absence of disease progression or
unacceptable toxicity.
ARM 2: Patients receive cabazitaxel and carboplatin IV over 60 minutes on day 1 of each
cycle and prednisone PO BID on days 1-21 of each cycle. Cycles repeat every 21 days for
up to 10 cycles in the absence of disease progression or unacceptable toxicity.
All patients undergo blood sample collection, bone scan, computed tomography (CT),
positron emission tomography (PET), or magnetic resonance imaging (MRI) throughout the
trial and chest radiography (x-ray) before randomization.
After completion of study treatment, patients are followed every 12 weeks for 1 year
after randomization, and then every 26 weeks for up to 4 years after randomization or
until death, whichever occurs first.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
- STEP 1 SCREENING REGISTRATION: NOTE: All participants must have biopsy tissue
submitted to MD Anderson Cancer Center prior to randomization for alteration
assessment. Participants must have determination of their AVPC-Molecular Pathologic
Signature immunohistochemistry (MSIHC) status from central assessment by the MD
Anderson Clinical Pathology Laboratory using Clinical Laboratory Improvement Act
(CLIA) certified immunohistochemistry (IHC) assays for TP53, RB1 and PTEN. In
addition, while not mandated, CLIA certified next generation sequencing (NGS) of
tumor deoxyribonucleic acid (DNA) and/or circulating tumor derived DNA (ctDNA)
assessment of AVPC-MS marker status will be collected from participants for whom it
is available
- STEP 1 SCREENING REGISTRATION: Participants must have a histologically confirmed
diagnosis of prostate cancer at the time of step 1 registration
- STEP 1 SCREENING REGISTRATION: Participants must have castrate-resistant prostate
cancer and metastatic disease by bone scan and/or CT/MRI (i.e., soft tissue,
visceral, lymph node)
- STEP 1 SCREENING REGISTRATION: Participants may have received any prior therapy, but
one must be docetaxel or contain docetaxel in either the castrate-sensitive and/or
castrate resistant disease state
- STEP 1 SCREENING REGISTRATION: Participants must be ≥ 18 years of age at the time of
step 1 screening registration
- STEP 1 SCREENING REGISTRATION: Participants must have solid tumor biopsy material
(formalin-fixed paraffin-embedded (FFPE) tissue blocks and/or 10 cut slides on
four-micron thick unstained positive charged slides of FFPE tissue) available for
submission for alterations in TP53, RB1 and PTEN by IHC using CLIA certified assays
in the MD Anderson Clinical Pathology Laboratory. This specimen is required for
central assessment of the AVPC-MSIHC regardless of whether the site has already
locally evaluated the AVPC-MS status
- STEP 1 SCREENING REGISTRATION: Tumor samples submitted for analysis must have been
collected within 12 months prior to step 1 screening registration. Samples from
metastatic lesions collected in the castrate-resistant disease state are preferable
but not mandatory. Samples obtained during the hormone-naive disease state are
acceptable if collected within 12 months of step 1 screening registration. If more
than one tumor sample exists, the sample obtained closest to the date of
registration should be submitted to MDACC for analysis
- NOTE: Sites will receive an email from Southwest Oncology Group (SWOG)
Statistics and Data Management Center containing participant results of
Aggressive Variant Prostate Cancer Molecular Signature (AVPC-MS) assessment
within 5-12 business days after tissue submission to MD Anderson Clinical
Pathology Laboratory. The participant's AVPC-MS signature result (positive or
negative) is required BEFORE randomization on to step 2. If sites receive a
non-evaluable AVPC-MS signature result, SWOG Statistics and Data Management
Center will provide instructions for resubmission
- STEP 1 SCREENING REGISTRATION: NOTE: As a part of the Oncology Patient Enrollment
Network (OPEN) registration process the treating institution's identity is provided
in order to ensure that the current (within 365 days) date of institutional review
board approval for this study has been entered in the system
- STEP 1 SCREENING REGISTRATION: Participants must be informed of the investigational
nature of this study and must sign and give informed consent in accordance with
institutional and federal guidelines. Documentation of informed consent via remote
consent is allowed
- For participants with impaired decision-making capabilities, legally authorized
representatives may sign and give informed consent on behalf of study
participants in accordance with applicable federal, local, and Central
Institutional Review Board (CIRB) regulations
- STEP 2 RANDOMIZATION: NOTE: Participants must be registered to step 2 randomization
within 70 days after registration to step 1. Participants must plan to start
protocol therapy no more than 14 days after step 2 randomization
- STEP 2 RANDOMIZATION: Participants must have castrate levels of testosterone with a
baseline level < 50ng/dL within 28 days prior to step 2 randomization
- STEP 2 RANDOMIZATION: Participants must have evidence for metastatic prostate cancer
by bone scan and/or CT/MRI (i.e., soft tissue, visceral, lymph node). Visceral
and/or soft-tissue metastases must be ≥ 1.0 cm in diameter and lymph nodes must be >
1.5 cm diameter in the short axis. Scans must be obtained within 28 days prior to
randomization
- NOTE: All disease must be assessed and documented on the
baseline/pre-registration tumor assessment form
- STEP 2 RANDOMZIATION: Participants must have progressive disease (PD) in the opinion
of the treating investigator according to any of the following criteria
- Progression in measurable disease (RECIST 1.1 criteria). Patient with
measurable disease must have at least one lesion that can be accurately
measured in at least one dimension (longest diameter to be recorded). Each
lesion must be at least 10 mm when measured by computed tomography (CT) [CT
scan thickness no greater than 5 mm] or magnetic resonance imaging (MRI). Lymph
nodes should be ≥ 15 mm in short axis. Previously irradiated lesions, primary
prostate lesion and bone lesions will be considered non-measurable disease
- Progression in bone as evidenced by:
- Appearance of 2 or more new bone lesions on bone scan (BS). If equivocal,
they must be confirmed by other imaging modalities (CT; MRI), and/or
repeat BS > 4 weeks later
- Appearance of a new lytic lesion(s) and/or increasing size of an existing
lesion by CT/MRI, since AVPC tumors may produce lytic bone lesions that
are not detected on conventional bone scans
- Rising prostate-specific antigen (PSA) defined (Prostate Cancer Working Group 2
[PCWG2]) as at least two consecutive rises in PSA to be documented over a
reference value (measure 1) taken at least one week apart. The first rising PSA
(measure 2) should be taken at least 7 days after the reference value. A third
confirmatory PSA measure is required (2nd beyond the reference level) to be
greater than the second measure and it must be obtained at least 7 days after
the 2nd measure. If this is not the case, a fourth PSA measure is required to
be taken and be greater than the 2nd measure. In case of progression based on
rising PSA only, the first rising PSA (measure 2) must be obtained within 6
months of initiation of androgen receptor (AR) targeted therapy (≤ 6 months)
- Clinical progression. Increasing symptoms unequivocally attributed to disease
progression as judged by the treating physician
- STEP 2 RANDOMIZATION: Participants must not have received prior cabazitaxel or
carboplatin
- STEP 2 RANDOMIZATION: Participants must not be receiving treatment on another
therapeutic clinical trial at the time of randomization. Chemotherapies, bone
targeting therapies, immunotherapies and clinical trial agents must be discontinued
≥ 21 days prior to randomization. Stereotactic radiation (SART) must be discontinued
≥ 3 days prior to randomization
- STEP 2 RANDOMIZATION: Participants must not be receiving radiation therapy or
kyphoplasty-vertebroplasty within 14 days prior to randomization or major surgery
(e.g., open abdominal, pelvic, thoracic, orthopedic or neurosurgery) within 28 days
prior to step 2 randomization
- STEP 2 RANDOMIZATION: Participants must not have untreated fractures and/or cord
compression
- STEP 2 RANDOMIZATION: Participants must not have symptomatic uncontrolled brain
metastases. Properly treated brain metastases (i.e., with stereotactic radiation)
within 14 days are allowed
- STEP 2 RANDOMIZATION: Participants must have Zubrod performance status of 0 - 2
within 28 days prior to step 2 randomization
- STEP 2 RANDOMIZATION: Participants must have a complete medical history and physical
exam within 28 days prior to step 2 randomization
- STEP 2 RANDOMIZATION: Absolute neutrophil count ≥ 1.5 x 10^3/uL (within 28 days
prior to step 2 randomization)
- STEP 2 RANDOMIZATION: Platelets ≥ 100 x 10^3/uL (unless clinical evidence of bone
marrow infiltration by tumor in which case > 75 x 10^3/uL are allowed) (within 28
days prior to step 2 randomization)
- STEP 2 RANDOMIZATION: Total bilirubin ≤ institutional upper limit of normal (ULN)
with the exception of isolated hyperbilirubinemia due to Gilbert's syndrome or if
the participant has liver metastases and/or acute tumor associated illness < 4x ULN
(within 28 days prior to step 2 randomization)
- STEP 2 RANDOMIZATION: Aspartate aminotransferase (AST)/alanine aminotransferase
(ALT) ≤ 3 × institutional ULN (or if participant has liver metastases and/or acute
tumor-associated illness, ≤ 4x institutional ULN) (within 28 days prior to step 2
randomization)
- STEP 2 REGISTRATION: Participants must have a calculated creatinine clearance ≥ 30
mL/min using the Cockcroft-Gault Formula. This specimen must have been drawn and
processed within 28 days prior to step 2 randomization
- STEP 2 RANDOMIZATION: Participants with peripheral neuropathy must have ≤ grade 2
peripheral neuropathy (Common Terminology Criteria for Adverse Events [CTCAE]
version 5.0) (within 28 days prior to step 2 randomization)
- STEP 2 RANDOMIZATION: Participants who are of reproductive potential must have
agreed to use an effective contraceptive method with details provided as a part of
the consent process. A person who has semen likely to contain sperm is considered to
be of "reproductive potential." In addition to routine contraceptive methods,
"effective contraception" also includes refraining from sexual activity that might
result in pregnancy and surgery intended to prevent pregnancy (or with a side-effect
of pregnancy prevention) including vasectomy with testing showing no sperm in the
semen
- STEP 2 RANDOMIZATION: Participants must not have a prior or concurrent malignancy
whose natural history or treatment (in the opinion of the treating physician) has
the potential to interfere with the safety or efficacy assessment of the treatment
regimen
- STEP 2 RANDOMIZATION: Participants with known human immunodeficiency virus
(HIV)-infection must be on effective anti-retroviral therapy at registration and
have undetectable viral load test on the most recent test results obtained within 6
months prior to registration
- STEP 2 RANDOMIZATION: Participants must be offered the opportunity to participate in
specimen banking. With participant consent, specimens must be collected and
submitted via the SWOG Specimen Tracking System
Gender:
Male
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
Highlands Oncology Group - Fayetteville
Address:
City:
Fayetteville
Zip:
72703
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
479-872-8100
Email:
research@hogonc.com
Investigator:
Last name:
Joseph T. Beck
Email:
Principal Investigator
Facility:
Name:
Highlands Oncology Group - Rogers
Address:
City:
Rogers
Zip:
72758
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
479-872-8130
Email:
research@hogonc.com
Investigator:
Last name:
Joseph T. Beck
Email:
Principal Investigator
Facility:
Name:
Highlands Oncology Group
Address:
City:
Springdale
Zip:
72762
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
479-872-8130
Email:
research@hogonc.com
Investigator:
Last name:
Joseph T. Beck
Email:
Principal Investigator
Facility:
Name:
Tibor Rubin VA Medical Center
Address:
City:
Long Beach
Zip:
90822
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
562-826-8000
Investigator:
Last name:
Pankaj Gupta
Email:
Principal Investigator
Facility:
Name:
Beebe Medical Center
Address:
City:
Lewes
Zip:
19958
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
302-291-6730
Email:
research@beebehealthcare.org
Investigator:
Last name:
Gregory A. Masters
Email:
Principal Investigator
Facility:
Name:
Beebe South Coastal Health Campus
Address:
City:
Millville
Zip:
19967
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
302-291-6730
Email:
research@beebehealthcare.org
Investigator:
Last name:
Gregory A. Masters
Email:
Principal Investigator
Facility:
Name:
Helen F Graham Cancer Center
Address:
City:
Newark
Zip:
19713
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
302-623-4450
Email:
lbarone@christianacare.org
Investigator:
Last name:
Gregory A. Masters
Email:
Principal Investigator
Facility:
Name:
Medical Oncology Hematology Consultants PA
Address:
City:
Newark
Zip:
19713
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
302-623-4450
Email:
lbarone@christianacare.org
Investigator:
Last name:
Gregory A. Masters
Email:
Principal Investigator
Facility:
Name:
Christiana Care Health System-Christiana Hospital
Address:
City:
Newark
Zip:
19718
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
302-623-4450
Email:
lbarone@christianacare.org
Investigator:
Last name:
Gregory A. Masters
Email:
Principal Investigator
Facility:
Name:
Beebe Health Campus
Address:
City:
Rehoboth Beach
Zip:
19971
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
302-291-6730
Email:
research@beebehealthcare.org
Investigator:
Last name:
Gregory A. Masters
Email:
Principal Investigator
Facility:
Name:
Christiana Care Health System-Wilmington Hospital
Address:
City:
Wilmington
Zip:
19801
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
302-623-4450
Email:
lbarone@christianacare.org
Investigator:
Last name:
Gregory A. Masters
Email:
Principal Investigator
Facility:
Name:
Holy Cross Hospital
Address:
City:
Fort Lauderdale
Zip:
33308
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Email:
eileen.georgi@holy-cross.com
Investigator:
Last name:
Elie G. Dib
Email:
Principal Investigator
Facility:
Name:
Saint Alphonsus Cancer Care Center-Boise
Address:
City:
Boise
Zip:
83706
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-3671
Email:
stephanie.couch@stjoeshealth.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
Saint Alphonsus Cancer Care Center-Caldwell
Address:
City:
Caldwell
Zip:
83605
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-3671
Email:
stephanie.couch@stjoeshealth.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
Kootenai Health - Coeur d'Alene
Address:
City:
Coeur d'Alene
Zip:
83814
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
406-969-6060
Email:
mccinfo@mtcancer.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
Idaho Urologic Institute-Meridian
Address:
City:
Meridian
Zip:
83642
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-3671
Email:
stephanie.couch@stjoeshealth.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
Saint Alphonsus Cancer Care Center-Nampa
Address:
City:
Nampa
Zip:
83687
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
406-969-6060
Email:
mccinfo@mtcancer.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
Kootenai Clinic Cancer Services - Post Falls
Address:
City:
Post Falls
Zip:
83854
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
406-969-6060
Email:
mccinfo@mtcancer.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
Kootenai Clinic Cancer Services - Sandpoint
Address:
City:
Sandpoint
Zip:
83864
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
406-969-6060
Email:
mccinfo@mtcancer.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
Illinois CancerCare-Bloomington
Address:
City:
Bloomington
Zip:
61704
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
309-243-3605
Email:
andersonj@illinoiscancercare.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Illinois CancerCare-Canton
Address:
City:
Canton
Zip:
61520
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
309-243-3605
Email:
andersonj@illinoiscancercare.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Memorial Hospital of Carbondale
Address:
City:
Carbondale
Zip:
62902
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
618-457-5200
Email:
clinical.research@sih.net
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
SIH Cancer Institute
Address:
City:
Carterville
Zip:
62918
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
618-985-3333
Email:
clinical.research@sih.net
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Illinois CancerCare-Carthage
Address:
City:
Carthage
Zip:
62321
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
309-243-3605
Email:
andersonj@illinoiscancercare.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Centralia Oncology Clinic
Address:
City:
Centralia
Zip:
62801
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
217-876-4762
Email:
morganthaler.jodi@mhsil.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Northwestern University
Address:
City:
Chicago
Zip:
60611
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
312-695-1301
Email:
cancer@northwestern.edu
Investigator:
Last name:
Maha H. Hussain
Email:
Principal Investigator
Facility:
Name:
University of Illinois
Address:
City:
Chicago
Zip:
60612
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
312-355-3046
Investigator:
Last name:
Natalie Reizine
Email:
Principal Investigator
Facility:
Name:
Cancer Care Specialists of Illinois - Decatur
Address:
City:
Decatur
Zip:
62526
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
217-876-4762
Email:
morganthaler.jodi@mhsil.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Decatur Memorial Hospital
Address:
City:
Decatur
Zip:
62526
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
217-876-4762
Email:
morganthaler.jodi@mhsil.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Northwestern Medicine Cancer Center Kishwaukee
Address:
City:
DeKalb
Zip:
60115
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
630-352-5360
Email:
Donald.Smith3@nm.org
Investigator:
Last name:
Maha H. Hussain
Email:
Principal Investigator
Facility:
Name:
Illinois CancerCare-Dixon
Address:
City:
Dixon
Zip:
61021
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
815-285-7800
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Crossroads Cancer Center
Address:
City:
Effingham
Zip:
62401
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
217-876-4762
Email:
morganthaler.jodi@mhsil.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Illinois CancerCare-Eureka
Address:
City:
Eureka
Zip:
61530
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
309-243-3605
Email:
andersonj@illinoiscancercare.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Illinois CancerCare-Galesburg
Address:
City:
Galesburg
Zip:
61401
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
309-243-3605
Email:
andersonj@illinoiscancercare.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Western Illinois Cancer Treatment Center
Address:
City:
Galesburg
Zip:
61401
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
309-344-2831
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Northwestern Medicine Cancer Center Delnor
Address:
City:
Geneva
Zip:
60134
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
630-352-5360
Email:
Donald.Smith3@nm.org
Investigator:
Last name:
Maha H. Hussain
Email:
Principal Investigator
Facility:
Name:
Northwestern Medicine Glenview Outpatient Center
Address:
City:
Glenview
Zip:
60026
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
312-695-1102
Investigator:
Last name:
Maha H. Hussain
Email:
Principal Investigator
Facility:
Name:
Northwestern Medicine Grayslake Outpatient Center
Address:
City:
Grayslake
Zip:
60030
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
312-695-1102
Investigator:
Last name:
Maha H. Hussain
Email:
Principal Investigator
Facility:
Name:
Illinois CancerCare-Kewanee Clinic
Address:
City:
Kewanee
Zip:
61443
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
309-243-3605
Email:
andersonj@illinoiscancercare.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Northwestern Medicine Lake Forest Hospital
Address:
City:
Lake Forest
Zip:
60045
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Email:
cancertrials@northwestern.edu
Investigator:
Last name:
Maha H. Hussain
Email:
Principal Investigator
Facility:
Name:
Illinois CancerCare-Macomb
Address:
City:
Macomb
Zip:
61455
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
309-243-3605
Email:
andersonj@illinoiscancercare.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Cancer Care Center of O'Fallon
Address:
City:
O'Fallon
Zip:
62269
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
217-876-4762
Email:
morganthaler.jodi@mhsil.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
HSHS Saint Elizabeth's Hospital
Address:
City:
O'Fallon
Zip:
62269
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
217-876-4762
Email:
morganthaler.jodi@mhsil.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Northwestern Medicine Orland Park
Address:
City:
Orland Park
Zip:
60462
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Email:
nctnprogram_rhlccc@northwestern.edu
Investigator:
Last name:
Maha H. Hussain
Email:
Principal Investigator
Facility:
Name:
Illinois CancerCare-Ottawa Clinic
Address:
City:
Ottawa
Zip:
61350
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
309-243-3605
Email:
andersonj@illinoiscancercare.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Illinois CancerCare-Pekin
Address:
City:
Pekin
Zip:
61554
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
309-243-3605
Email:
andersonj@illinoiscancercare.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Illinois CancerCare-Peoria
Address:
City:
Peoria
Zip:
61615
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
309-243-3605
Email:
andersonj@illinoiscancercare.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Methodist Medical Center of Illinois
Address:
City:
Peoria
Zip:
61636
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
309-243-3605
Email:
andersonj@illinoiscancercare.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Illinois CancerCare-Peru
Address:
City:
Peru
Zip:
61354
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
309-243-3605
Email:
andersonj@illinoiscancercare.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Valley Radiation Oncology
Address:
City:
Peru
Zip:
61354
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
815-664-4141
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Illinois CancerCare-Princeton
Address:
City:
Princeton
Zip:
61356
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
309-243-3605
Email:
andersonj@illinoiscancercare.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Southern Illinois University School of Medicine
Address:
City:
Springfield
Zip:
62702
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
217-545-7929
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Springfield Clinic
Address:
City:
Springfield
Zip:
62702
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-444-7541
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Memorial Medical Center
Address:
City:
Springfield
Zip:
62781
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
217-528-7541
Email:
pallante.beth@mhsil.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Northwestern Medicine Cancer Center Warrenville
Address:
City:
Warrenville
Zip:
60555
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
630-352-5360
Email:
Donald.Smith3@nm.org
Investigator:
Last name:
Maha H. Hussain
Email:
Principal Investigator
Facility:
Name:
Illinois CancerCare - Washington
Address:
City:
Washington
Zip:
61571
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
309-243-3605
Email:
andersonj@illinoiscancercare.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Reid Health
Address:
City:
Richmond
Zip:
47374
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
937-528-2900
Email:
clinical.trials@daytonncorp.org
Investigator:
Last name:
Howard M. Gross
Email:
Principal Investigator
Facility:
Name:
Mercy Hospital
Address:
City:
Cedar Rapids
Zip:
52403
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
319-365-4673
Investigator:
Last name:
Deborah W. Wilbur
Email:
Principal Investigator
Facility:
Name:
Oncology Associates at Mercy Medical Center
Address:
City:
Cedar Rapids
Zip:
52403
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
319-363-2690
Investigator:
Last name:
Deborah W. Wilbur
Email:
Principal Investigator
Facility:
Name:
Christiana Care - Union Hospital
Address:
City:
Elkton
Zip:
21921
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
410-443-1360
Email:
frank.crum@christianacare.org
Investigator:
Last name:
Gregory A. Masters
Email:
Principal Investigator
Facility:
Name:
Trinity Health Saint Joseph Mercy Hospital Ann Arbor
Address:
City:
Ann Arbor
Zip:
48106
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-7251
Email:
MCRCwebsitecontactform@stjoeshealth.org
Investigator:
Last name:
Elie G. Dib
Email:
Principal Investigator
Facility:
Name:
Trinity Health IHA Medical Group Hematology Oncology - Brighton
Address:
City:
Brighton
Zip:
48114
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-7251
Email:
MCRCwebsitecontactform@stjoeshealth.org
Investigator:
Last name:
Elie G. Dib
Email:
Principal Investigator
Facility:
Name:
Trinity Health Medical Center - Brighton
Address:
City:
Brighton
Zip:
48114
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-7251
Email:
MCRCwebsitecontactform@stjoeshealth.org
Investigator:
Last name:
Elie G. Dib
Email:
Principal Investigator
Facility:
Name:
Trinity Health IHA Medical Group Hematology Oncology - Canton
Address:
City:
Canton
Zip:
48188
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-7251
Email:
MCRCwebsitecontactform@stjoeshealth.org
Investigator:
Last name:
Elie G. Dib
Email:
Principal Investigator
Facility:
Name:
Trinity Health Medical Center - Canton
Address:
City:
Canton
Zip:
48188
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-7251
Email:
MCRCwebsitecontactform@stjoeshealth.org
Investigator:
Last name:
Elie G. Dib
Email:
Principal Investigator
Facility:
Name:
Caro Cancer Center
Address:
City:
Caro
Zip:
48723
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
989-907-8411
Email:
lori.srebinski@ascension.org
Investigator:
Last name:
Elie G. Dib
Email:
Principal Investigator
Facility:
Name:
Chelsea Hospital
Address:
City:
Chelsea
Zip:
48118
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-7251
Email:
MCRCwebsitecontactform@stjoeshealth.org
Investigator:
Last name:
Elie G. Dib
Email:
Principal Investigator
Facility:
Name:
Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
Address:
City:
Chelsea
Zip:
48118
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-7251
Email:
MCRCwebsitecontactform@stjoeshealth.org
Investigator:
Last name:
Elie G. Dib
Email:
Principal Investigator
Facility:
Name:
Hematology Oncology Consultants-Clarkston
Address:
City:
Clarkston
Zip:
48346
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-7251
Email:
MCRCwebsitecontactform@stjoeshealth.org
Investigator:
Last name:
Elie G. Dib
Email:
Principal Investigator
Facility:
Name:
Newland Medical Associates-Clarkston
Address:
City:
Clarkston
Zip:
48346
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-7251
Email:
MCRCwebsitecontactform@stjoeshealth.org
Investigator:
Last name:
Elie G. Dib
Email:
Principal Investigator
Facility:
Name:
Henry Ford Health Saint John Hospital
Address:
City:
Detroit
Zip:
48236
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
313-343-3166
Email:
Kkeenan1@hfhs.org
Investigator:
Last name:
Elie G. Dib
Email:
Principal Investigator
Facility:
Name:
Great Lakes Cancer Management Specialists-Doctors Park
Address:
City:
East China Township
Zip:
48054
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
313-343-3166
Email:
kforman1@hfhs.org
Investigator:
Last name:
Elie G. Dib
Email:
Principal Investigator
Facility:
Name:
Genesee Cancer and Blood Disease Treatment Center
Address:
City:
Flint
Zip:
48503
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
810-762-8038
Email:
wstrong@ghci.org
Investigator:
Last name:
Elie G. Dib
Email:
Principal Investigator
Facility:
Name:
Genesee Hematology Oncology PC
Address:
City:
Flint
Zip:
48503
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
810-762-8038
Email:
wstrong@ghci.org
Investigator:
Last name:
Elie G. Dib
Email:
Principal Investigator
Facility:
Name:
Genesys Hurley Cancer Institute
Address:
City:
Flint
Zip:
48503
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
810-762-8038
Email:
wstrong@ghci.org
Investigator:
Last name:
Elie G. Dib
Email:
Principal Investigator
Facility:
Name:
Hurley Medical Center
Address:
City:
Flint
Zip:
48503
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
810-762-8038
Email:
wstrong@ghci.org
Investigator:
Last name:
Elie G. Dib
Email:
Principal Investigator
Facility:
Name:
Great Lakes Cancer Management Specialists-Van Elslander Cancer Center
Address:
City:
Grosse Pointe Woods
Zip:
48236
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
313-343-3166
Email:
kforman1@hfhs.org
Investigator:
Last name:
Elie G. Dib
Email:
Principal Investigator
Facility:
Name:
Henry Ford Saint John Hospital - Academic
Address:
City:
Grosse Pointe Woods
Zip:
48236
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
313-343-3166
Email:
kforman1@hfhs.org
Investigator:
Last name:
Elie G. Dib
Email:
Principal Investigator
Facility:
Name:
Henry Ford Saint John Hospital - Breast
Address:
City:
Grosse Pointe Woods
Zip:
48236
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
313-343-3166
Email:
karen.forman@ascension.org
Investigator:
Last name:
Elie G. Dib
Email:
Principal Investigator
Facility:
Name:
University of Michigan Health - Sparrow Lansing
Address:
City:
Lansing
Zip:
48912
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
517-364-3712
Email:
harsha.trivedi@umhsparrow.org
Investigator:
Last name:
Elie G. Dib
Email:
Principal Investigator
Facility:
Name:
Trinity Health Saint Mary Mercy Livonia Hospital
Address:
City:
Livonia
Zip:
48154
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-7251
Email:
MCRCwebsitecontactform@stjoeshealth.org
Investigator:
Last name:
Elie G. Dib
Email:
Principal Investigator
Facility:
Name:
Great Lakes Cancer Management Specialists-Macomb Medical Campus
Address:
City:
Macomb
Zip:
48044
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
313-343-3166
Email:
kforman1@hfhs.org
Investigator:
Last name:
Elie G. Dib
Email:
Principal Investigator
Facility:
Name:
Henry Ford Warren Hospital - Breast Macomb
Address:
City:
Macomb
Zip:
48044
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
313-343-3166
Email:
kforman1@hfhs.org
Investigator:
Last name:
Elie G. Dib
Email:
Principal Investigator
Facility:
Name:
Saint Mary's Oncology/Hematology Associates of Marlette
Address:
City:
Marlette
Zip:
48453
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
989-907-8411
Email:
lori.srebinski@ascension.org
Investigator:
Last name:
Elie G. Dib
Email:
Principal Investigator
Facility:
Name:
Hope Cancer Center
Address:
City:
Pontiac
Zip:
48341
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-7251
Email:
MCRCwebsitecontactform@stjoeshealth.org
Investigator:
Last name:
Elie G. Dib
Email:
Principal Investigator
Facility:
Name:
Michigan Healthcare Professionals Pontiac
Address:
City:
Pontiac
Zip:
48341
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
248-858-6215
Email:
Emily.Crofts@trinity-health.org
Investigator:
Last name:
Elie G. Dib
Email:
Principal Investigator
Facility:
Name:
Newland Medical Associates-Pontiac
Address:
City:
Pontiac
Zip:
48341
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-7251
Email:
MCRCwebsitecontactform@stjoeshealth.org
Investigator:
Last name:
Elie G. Dib
Email:
Principal Investigator
Facility:
Name:
Trinity Health Saint Joseph Mercy Oakland Hospital
Address:
City:
Pontiac
Zip:
48341
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-7251
Email:
MCRCwebsitecontactform@stjoeshealth.org
Investigator:
Last name:
Elie G. Dib
Email:
Principal Investigator
Facility:
Name:
MyMichigan Medical Center Saginaw
Address:
City:
Saginaw
Zip:
48601
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-7251
Email:
MCRCwebsitecontactform@stjoeshealth.org
Investigator:
Last name:
Elie G. Dib
Email:
Principal Investigator
Facility:
Name:
Oncology Hematology Associates of Saginaw Valley PC
Address:
City:
Saginaw
Zip:
48604
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
989-907-8411
Email:
lori.srebinski@ascension.org
Investigator:
Last name:
Elie G. Dib
Email:
Principal Investigator
Facility:
Name:
MyMichigan Medical Center Tawas
Address:
City:
Tawas City
Zip:
48764
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-7251
Email:
MCRCwebsitecontactform@stjoeshealth.org
Investigator:
Last name:
Elie G. Dib
Email:
Principal Investigator
Facility:
Name:
Great Lakes Cancer Management Specialists-Macomb Professional Building
Address:
City:
Warren
Zip:
48093
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
313-343-3166
Email:
kforman1@hfhs.org
Investigator:
Last name:
Elie G. Dib
Email:
Principal Investigator
Facility:
Name:
Henry Ford Madison Heights Hospital - Breast
Address:
City:
Warren
Zip:
48093
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
313-343-3166
Email:
kforman1@hfhs.org
Investigator:
Last name:
Elie G. Dib
Email:
Principal Investigator
Facility:
Name:
Saint John Macomb-Oakland Hospital
Address:
City:
Warren
Zip:
48093
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
313-343-3166
Email:
kforman1@hfhs.org
Investigator:
Last name:
Elie G. Dib
Email:
Principal Investigator
Facility:
Name:
Saint Mary's Oncology/Hematology Associates of West Branch
Address:
City:
West Branch
Zip:
48661
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
989-907-8411
Email:
lori.srebinski@ascension.org
Investigator:
Last name:
Elie G. Dib
Email:
Principal Investigator
Facility:
Name:
Huron Gastroenterology PC
Address:
City:
Ypsilanti
Zip:
48106
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-7251
Email:
MCRCwebsitecontactform@stjoeshealth.org
Investigator:
Last name:
Elie G. Dib
Email:
Principal Investigator
Facility:
Name:
Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
Address:
City:
Ypsilanti
Zip:
48197
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-7251
Email:
MCRCwebsitecontactform@stjoeshealth.org
Investigator:
Last name:
Elie G. Dib
Email:
Principal Investigator
Facility:
Name:
Minnesota Oncology - Burnsville
Address:
City:
Burnsville
Zip:
55337
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
952-993-1517
Email:
mmcorc@healthpartners.com
Investigator:
Last name:
David M. King
Email:
Principal Investigator
Facility:
Name:
Cambridge Medical Center
Address:
City:
Cambridge
Zip:
55008
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
952-993-1517
Email:
mmcorc@healthpartners.com
Investigator:
Last name:
David M. King
Email:
Principal Investigator
Facility:
Name:
Mercy Hospital
Address:
City:
Coon Rapids
Zip:
55433
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
952-993-1517
Email:
mmcorc@healthpartners.com
Investigator:
Last name:
David M. King
Email:
Principal Investigator
Facility:
Name:
Fairview Southdale Hospital
Address:
City:
Edina
Zip:
55435
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
952-993-1517
Email:
mmcorc@healthpartners.com
Investigator:
Last name:
David M. King
Email:
Principal Investigator
Facility:
Name:
Fairview Clinics and Surgery Center Maple Grove
Address:
City:
Maple Grove
Zip:
55369
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
952-993-1517
Email:
mmcorc@healthpartners.com
Investigator:
Last name:
David M. King
Email:
Principal Investigator
Facility:
Name:
Minnesota Oncology Hematology PA-Maplewood
Address:
City:
Maplewood
Zip:
55109
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
952-993-1517
Email:
mmcorc@healthpartners.com
Investigator:
Last name:
David M. King
Email:
Principal Investigator
Facility:
Name:
Saint John's Hospital - Healtheast
Address:
City:
Maplewood
Zip:
55109
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
952-993-1517
Email:
mmcorc@healthpartners.com
Investigator:
Last name:
David M. King
Email:
Principal Investigator
Facility:
Name:
Abbott-Northwestern Hospital
Address:
City:
Minneapolis
Zip:
55407
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
952-993-1517
Email:
mmcorc@healthpartners.com
Investigator:
Last name:
David M. King
Email:
Principal Investigator
Facility:
Name:
Hennepin County Medical Center
Address:
City:
Minneapolis
Zip:
55415
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
952-993-1517
Email:
mmcorc@healthpartners.com
Investigator:
Last name:
David M. King
Email:
Principal Investigator
Facility:
Name:
Health Partners Inc
Address:
City:
Minneapolis
Zip:
55454
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
952-993-1517
Email:
mmcorc@healthpartners.com
Investigator:
Last name:
David M. King
Email:
Principal Investigator
Facility:
Name:
Monticello Cancer Center
Address:
City:
Monticello
Zip:
55362
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
952-993-1517
Email:
mmcorc@healthpartners.com
Investigator:
Last name:
David M. King
Email:
Principal Investigator
Facility:
Name:
New Ulm Medical Center
Address:
City:
New Ulm
Zip:
56073
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
952-993-1517
Email:
mmcorc@healthpartners.com
Investigator:
Last name:
David M. King
Email:
Principal Investigator
Facility:
Name:
Fairview Northland Medical Center
Address:
City:
Princeton
Zip:
55371
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
952-993-1517
Email:
mmcorc@healthpartners.com
Investigator:
Last name:
David M. King
Email:
Principal Investigator
Facility:
Name:
North Memorial Medical Health Center
Address:
City:
Robbinsdale
Zip:
55422
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
952-993-1517
Email:
mmcorc@healthpartners.com
Investigator:
Last name:
David M. King
Email:
Principal Investigator
Facility:
Name:
Park Nicollet Clinic - Saint Louis Park
Address:
City:
Saint Louis Park
Zip:
55416
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
952-993-1517
Email:
mmcorc@healthpartners.com
Investigator:
Last name:
David M. King
Email:
Principal Investigator
Facility:
Name:
Regions Hospital
Address:
City:
Saint Paul
Zip:
55101
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
952-993-1517
Email:
mmcorc@healthpartners.com
Investigator:
Last name:
David M. King
Email:
Principal Investigator
Facility:
Name:
United Hospital
Address:
City:
Saint Paul
Zip:
55102
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
952-993-1517
Email:
mmcorc@healthpartners.com
Investigator:
Last name:
David M. King
Email:
Principal Investigator
Facility:
Name:
Saint Francis Regional Medical Center
Address:
City:
Shakopee
Zip:
55379
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
952-993-1517
Email:
mmcorc@healthpartners.com
Investigator:
Last name:
David M. King
Email:
Principal Investigator
Facility:
Name:
Lakeview Hospital
Address:
City:
Stillwater
Zip:
55082
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
952-993-1517
Email:
mmcorc@healthpartners.com
Investigator:
Last name:
David M. King
Email:
Principal Investigator
Facility:
Name:
Ridgeview Medical Center
Address:
City:
Waconia
Zip:
55387
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
952-993-1517
Email:
mmcorc@healthpartners.com
Investigator:
Last name:
David M. King
Email:
Principal Investigator
Facility:
Name:
Rice Memorial Hospital
Address:
City:
Willmar
Zip:
56201
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
952-993-1517
Email:
mmcorc@healthpartners.com
Investigator:
Last name:
David M. King
Email:
Principal Investigator
Facility:
Name:
Minnesota Oncology Hematology PA-Woodbury
Address:
City:
Woodbury
Zip:
55125
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
952-993-1517
Email:
mmcorc@healthpartners.com
Investigator:
Last name:
David M. King
Email:
Principal Investigator
Facility:
Name:
Fairview Lakes Medical Center
Address:
City:
Wyoming
Zip:
55092
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
952-993-1517
Email:
mmcorc@healthpartners.com
Investigator:
Last name:
David M. King
Email:
Principal Investigator
Facility:
Name:
University of Mississippi Medical Center
Address:
City:
Jackson
Zip:
39216
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
601-815-6700
Investigator:
Last name:
John C. Henegan
Email:
Principal Investigator
Facility:
Name:
Saint Francis Medical Center
Address:
City:
Cape Girardeau
Zip:
63703
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
573-334-2230
Email:
sfmc@sfmc.net
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Southeast Cancer Center
Address:
City:
Cape Girardeau
Zip:
63703
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
573-651-5550
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Parkland Health Center - Farmington
Address:
City:
Farmington
Zip:
63640
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
314-996-5569
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Missouri Baptist Medical Center
Address:
City:
Saint Louis
Zip:
63131
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
314-996-5569
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Sainte Genevieve County Memorial Hospital
Address:
City:
Sainte Genevieve
Zip:
63670
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
314-996-5569
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Missouri Baptist Sullivan Hospital
Address:
City:
Sullivan
Zip:
63080
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
314-996-5569
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
BJC Outpatient Center at Sunset Hills
Address:
City:
Sunset Hills
Zip:
63127
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
314-996-5569
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Community Hospital of Anaconda
Address:
City:
Anaconda
Zip:
59711
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
406-969-6060
Email:
mccinfo@mtcancer.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
Billings Clinic Cancer Center
Address:
City:
Billings
Zip:
59101
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-996-2663
Email:
research@billingsclinic.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
Bozeman Health Deaconess Hospital
Address:
City:
Bozeman
Zip:
59715
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
406-969-6060
Email:
mccinfo@mtcancer.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
Benefis Sletten Cancer Institute
Address:
City:
Great Falls
Zip:
59405
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
406-969-6060
Email:
mccinfo@mtcancer.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
Great Falls Clinic
Address:
City:
Great Falls
Zip:
59405
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
406-969-6060
Email:
mccinfo@mtcancer.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
Kalispell Regional Medical Center
Address:
City:
Kalispell
Zip:
59901
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
406-969-6060
Email:
mccinfo@mtcancer.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
Community Medical Center
Address:
City:
Missoula
Zip:
59804
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
406-969-6060
Email:
mccinfo@mtcancer.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
Nebraska Medicine-Bellevue
Address:
City:
Bellevue
Zip:
68123
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
402-559-6941
Email:
unmcrsa@unmc.edu
Investigator:
Last name:
Benjamin A. Teply
Email:
Principal Investigator
Facility:
Name:
Nebraska Medicine-Village Pointe
Address:
City:
Omaha
Zip:
68118
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
402-559-5600
Investigator:
Last name:
Benjamin A. Teply
Email:
Principal Investigator
Facility:
Name:
University of Nebraska Medical Center
Address:
City:
Omaha
Zip:
68198
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
402-559-6941
Email:
unmcrsa@unmc.edu
Investigator:
Last name:
Benjamin A. Teply
Email:
Principal Investigator
Facility:
Name:
Indu and Raj Soin Medical Center
Address:
City:
Beavercreek
Zip:
45431
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
937-528-2900
Email:
clinical.trials@daytonncorp.org
Investigator:
Last name:
Howard M. Gross
Email:
Principal Investigator
Facility:
Name:
Saint Elizabeth Boardman Hospital
Address:
City:
Boardman
Zip:
44512
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
937-528-2900
Email:
clinical.trials@daytonncorp.org
Investigator:
Last name:
Howard M. Gross
Email:
Principal Investigator
Facility:
Name:
Dayton Physicians LLC-Miami Valley South
Address:
City:
Centerville
Zip:
45459
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
937-528-2900
Email:
clinical.trials@daytonncorp.org
Investigator:
Last name:
Howard M. Gross
Email:
Principal Investigator
Facility:
Name:
Oncology Hematology Care Inc-Kenwood
Address:
City:
Cincinnati
Zip:
45236
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
937-528-2900
Email:
clinical.trials@daytonncorp.org
Investigator:
Last name:
Howard M. Gross
Email:
Principal Investigator
Facility:
Name:
Dayton Physician LLC - Englewood
Address:
City:
Dayton
Zip:
45415
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
937-528-2900
Email:
clinical.trials@daytonncorp.org
Investigator:
Last name:
Howard M. Gross
Email:
Principal Investigator
Facility:
Name:
Armes Family Cancer Center
Address:
City:
Findlay
Zip:
45840
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
937-528-2900
Email:
clinical.trials@daytonncorp.org
Investigator:
Last name:
Howard M. Gross
Email:
Principal Investigator
Facility:
Name:
Blanchard Valley Hospital
Address:
City:
Findlay
Zip:
45840
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
937-528-2900
Email:
clinical.trials@daytonncorp.org
Investigator:
Last name:
Howard M. Gross
Email:
Principal Investigator
Facility:
Name:
Orion Cancer Care
Address:
City:
Findlay
Zip:
45840
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
937-528-2900
Email:
clinical.trials@daytonncorp.org
Investigator:
Last name:
Howard M. Gross
Email:
Principal Investigator
Facility:
Name:
Dayton Physicians LLC-Atrium
Address:
City:
Franklin
Zip:
45005
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
937-528-2900
Email:
clinical.trials@daytonncorp.org
Investigator:
Last name:
Howard M. Gross
Email:
Principal Investigator
Facility:
Name:
Dayton Physicians LLC-Wayne
Address:
City:
Greenville
Zip:
45331
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
937-528-2900
Email:
clinical.trials@daytonncorp.org
Investigator:
Last name:
Howard M. Gross
Email:
Principal Investigator
Facility:
Name:
Wayne Hospital
Address:
City:
Greenville
Zip:
45331
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
937-528-2900
Email:
clinical.trials@daytonncorp.org
Investigator:
Last name:
Howard M. Gross
Email:
Principal Investigator
Facility:
Name:
Greater Dayton Cancer Center
Address:
City:
Kettering
Zip:
45409
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
937-528-2900
Email:
clinical.trials@daytonncorp.org
Investigator:
Last name:
Howard M. Gross
Email:
Principal Investigator
Facility:
Name:
Kettering Medical Center
Address:
City:
Kettering
Zip:
45429
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
937-528-2900
Email:
clinical.trials@daytonncorp.org
Investigator:
Last name:
Howard M. Gross
Email:
Principal Investigator
Facility:
Name:
Dayton Physicians LLC - Troy
Address:
City:
Troy
Zip:
45373
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
937-528-2900
Email:
clinical.trials@daytonncorp.org
Investigator:
Last name:
Howard M. Gross
Email:
Principal Investigator
Facility:
Name:
Saint Joseph Warren Hospital
Address:
City:
Warren
Zip:
44484
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
937-528-2900
Email:
clinical.trials@daytonncorp.org
Investigator:
Last name:
Howard M. Gross
Email:
Principal Investigator
Facility:
Name:
Saint Elizabeth Youngstown Hospital
Address:
City:
Youngstown
Zip:
44501
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
937-528-2900
Email:
clinical.trials@daytonncorp.org
Investigator:
Last name:
Howard M. Gross
Email:
Principal Investigator
Facility:
Name:
University of Oklahoma Health Sciences Center
Address:
City:
Oklahoma City
Zip:
73104
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
405-271-8777
Email:
ou-clinical-trials@ouhsc.edu
Investigator:
Last name:
Adanma Anji Ayanambakkam Attanathi
Email:
Principal Investigator
Facility:
Name:
Saint Alphonsus Cancer Care Center-Baker City
Address:
City:
Baker City
Zip:
97814
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
406-969-6060
Email:
mccinfo@mtcancer.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
Saint Alphonsus Cancer Care Center-Ontario
Address:
City:
Ontario
Zip:
97914
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
406-969-6060
Email:
mccinfo@mtcancer.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
Lehigh Valley Hospital-Cedar Crest
Address:
City:
Allentown
Zip:
18103
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
610-402-9543
Email:
Morgan_M.Horton@lvhn.org
Investigator:
Last name:
Elie G. Dib
Email:
Principal Investigator
Facility:
Name:
Lehigh Valley Hospital - Muhlenberg
Address:
City:
Bethlehem
Zip:
18017
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
610-402-9543
Email:
Morgan_M.Horton@lvhn.org
Investigator:
Last name:
Elie G. Dib
Email:
Principal Investigator
Facility:
Name:
Christiana Care Health System-Concord Health Center
Address:
City:
Chadds Ford
Zip:
19317
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
302-623-4450
Email:
lbarone@christianacare.org
Investigator:
Last name:
Gregory A. Masters
Email:
Principal Investigator
Facility:
Name:
Pocono Medical Center
Address:
City:
East Stroudsburg
Zip:
18301
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
610-402-9543
Email:
Morgan_M.Horton@lvhn.org
Investigator:
Last name:
Elie G. Dib
Email:
Principal Investigator
Facility:
Name:
Lehigh Valley Hospital-Hazleton
Address:
City:
Hazleton
Zip:
18201
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
610-402-9543
Email:
Morgan_M.Horton@lvhn.org
Investigator:
Last name:
Elie G. Dib
Email:
Principal Investigator
Facility:
Name:
The West Clinic - Wolf River
Address:
City:
Germantown
Zip:
38138
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
901-683-0055
Email:
afletcher@westclinic.com
Investigator:
Last name:
Bradley G. Somer
Email:
Principal Investigator
Facility:
Name:
MD Anderson in The Woodlands
Address:
City:
Conroe
Zip:
77384
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
866-632-6789
Email:
askmdanderson@mdanderson.org
Investigator:
Last name:
Paul Corn
Email:
Principal Investigator
Facility:
Name:
Lyndon Baines Johnson General Hospital
Address:
City:
Houston
Zip:
77026-1967
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
713-566-5000
Investigator:
Last name:
Paul Corn
Email:
Principal Investigator
Facility:
Name:
M D Anderson Cancer Center
Address:
City:
Houston
Zip:
77030
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
877-632-6789
Email:
askmdanderson@mdanderson.org
Investigator:
Last name:
Paul Corn
Email:
Principal Investigator
Facility:
Name:
MD Anderson West Houston
Address:
City:
Houston
Zip:
77079
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
877-632-6789
Email:
askmdanderson@mdanderson.org
Investigator:
Last name:
Paul Corn
Email:
Principal Investigator
Facility:
Name:
MD Anderson League City
Address:
City:
League City
Zip:
77573
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
877-632-6789
Email:
askmdanderson@mdanderson.org
Investigator:
Last name:
Paul Corn
Email:
Principal Investigator
Facility:
Name:
MD Anderson in Sugar Land
Address:
City:
Sugar Land
Zip:
77478
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
877-632-6789
Email:
askmdanderson@mdanderson.org
Investigator:
Last name:
Paul Corn
Email:
Principal Investigator
Facility:
Name:
VCU Massey Cancer Center at Stony Point
Address:
City:
Richmond
Zip:
23235
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Email:
ctoclinops@vcu.edu
Investigator:
Last name:
John Melson
Email:
Principal Investigator
Facility:
Name:
Virginia Commonwealth University/Massey Cancer Center
Address:
City:
Richmond
Zip:
23298
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Email:
CTOclinops@vcu.edu
Investigator:
Last name:
John Melson
Email:
Principal Investigator
Facility:
Name:
Cancer Center of Western Wisconsin
Address:
City:
New Richmond
Zip:
54017
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
952-993-1517
Email:
mmcorc@healthpartners.com
Investigator:
Last name:
David M. King
Email:
Principal Investigator
Facility:
Name:
Billings Clinic-Cody
Address:
City:
Cody
Zip:
82414
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-996-2663
Email:
research@billingsclinic.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
Welch Cancer Center
Address:
City:
Sheridan
Zip:
82801
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
406-969-6060
Email:
mccinfo@mtcancer.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Start date:
December 12, 2024
Completion date:
April 2032
Lead sponsor:
Agency:
SWOG Cancer Research Network
Agency class:
Other
Collaborator:
Agency:
National Cancer Institute (NCI)
Agency class:
NIH
Source:
SWOG Cancer Research Network
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT06470243
